This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We would like to thank Drs. Xu and Hu for their response on our recently published meta-analysis on the safety and efficacy of dual antiplatelet pretreatment in patients with ischemic stroke treated with intravenous thrombolysis.1 We would like to highlight that the 2 studies mentioned by Drs. Xu and Hu do not have overlapping patients2,3 because the University of Tennessee Health Science Center (UTHSC) does not participate in the SITS registry. Therefore, stroke patients included in the single center study from UTHSC2 cannot overlap with patients from the Safe Implementation of Thrombolysis in Stroke registry cohort.3 Therefore, there is no concern for overlapping patient data in our meta-analysis. Responding to Drs. Xu and Hu's second concern, we would like to note that both of these studies2,3 provide unadjusted (raw) and adjusted estimates (after propensity score matching) on the association between dual antiplatelet pretreatment and the risk of symptomatic intracranial hemorrhage (SICH) after intravenous thrombolysis. These unadjusted and adjusted estimates are included in figure 1A and figure 2A of our meta-analysis, respectively.1 Of interest to the readers of the journal, the lack of association between dual antiplatelet pretreatment with the risk of SICH after intravenous thrombolysis has very recently been confirmed by an independent publication from the Thrombolysis in Stroke Patients (TRISP) collaborators.4
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
